Testing effectiveness (Phase 2)Study completedNCT02229084What this trial is testingVaccination of High Risk Breast Cancer PatientsWho this might be right forBreast CancerBreast Neoplasms University of Arkansas 58
Early research (Phase 1)Study completedNCT03364348What this trial is testing4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast CancerWho this might be right forHER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage III Breast Cancer+4 more George W. Sledge Jr. 18
Not applicableStudy completedNCT06961331What this trial is testingReal World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.Who this might be right forMetastatic HER2+ Advanced Breast Cancer Pfizer 86
Large-scale testing (Phase 3)Temporarily pausedNCT05503108What this trial is testingFasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast CancerWho this might be right forFasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more Leiden University Medical Center 10
Not applicableNot Yet RecruitingNCT05980208What this trial is testingA Real-world Study of Inetetamab for First-line Treatment of MBCWho this might be right forBreast CancerReal-world Study Hunan Cancer Hospital 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT04829604What this trial is testingARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Who this might be right forHER2 Positive Metastatic Breast Cancer Ambrx, Inc. 72
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094What this trial is testingTrial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsHER2-positive Breast Cancer Hoffmann-La Roche 210
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287What this trial is testingSHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyWho this might be right forSHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more Tianjin Medical University Cancer Institute and Hospital 30